Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei

Kathrine Bjersand, MD¹, Haile Mahteme, MD, PhD², Inger Sundström Poromaa, MD, PhD¹, Håkan Andréasson, MD, PhD², Wilhelm Graf, MD, PhD², Rolf Larsson, MD, PhD³, and Peter Nygren, MD, PhD⁴

¹Department of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden; ²Department of Surgical Sciences, Uppsala University, Uppsala, Sweden; ³Department of Medical Sciences, Uppsala University, Uppsala, Sweden; ⁴Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

ABSTRACT

Background. Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) is an established therapy for pseudomyxoma peritonei (PMP). However, the role of IPC is unclear. By ex vivo assessment of PMP tumor cell sensitivity to cytotoxic drugs, we investigated the basis for IPC drug selection and the role of IPC in the management of PMP.

Methods. Tumor cells were prepared by collagenase digestion of tumor tissue from 133 PMP patients planned for CRS and IPC. Tumor cell sensitivity to oxaliplatin, 5FU, mitomycin C, doxorubicin, irinotecan, and cisplatin was assessed in a 72-h cell-viability assay. Drug sensitivity was correlated to progression-free survival (PFS) and overall survival (OS).

Results. Samples from 92 patients were analyzed successfully. Drug sensitivity varied considerably between samples. Peritoneal mucinous carcinomatosis (PMCA), compared with PMCA intermediate or disseminated peritoneal adenomucinosis, was slightly more resistant to platinum and 5FU and tumor cells from patients previously treated with chemotherapy were generally less sensitive than those from untreated patients. Multivariate analysis showed patient performance status and completeness of CRS to be prognostic for OS. Among patients with complete CRS (n = 61), PFS tended to be associated with sensitivity to mitomycin C and cisplatin (p ≈ 0.06). At the highest drug concentration tested, the hazard ratio for disease relapse increased stepwise with drug resistance for all drugs.

Conclusions. Ex vivo assessment of drug sensitivity in PMP provides prognostic information. The results suggest a role for IPC as therapeutic adjunct to CRS and for individualization of IPC by pretreatment assessment of drug sensitivity.

Pseudomyxoma peritonei (PMP) is a rare tumor disease characterized by disseminated mucus and mucinous tumor tissue implants on the peritoneal surfaces, now considered to originate from the appendix.¹ By use of cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (IPC), as introduced by Sugarbaker, with the IPC now mostly being hyperthermic (HIPEC), the prognosis has improved.² Thus, experienced centres report a 5-year overall survival (OS) in the range of 70–95 % compared with 30–40 % often reported for the strategy of debulking surgery.³⁻⁵ The main factors associated with favorable prognosis are complete CRS, low tumor load, and low histological grade.⁵

Systemic chemotherapy alone as treatment of PMP has not been extensively investigated but seems poorly active in this disease.⁶ However, the role of the chemotherapy part of the CRS and IPC treatment package in PMP is unclear. Thus, the effect of CRS with or without IPC has not been directly compared and long-term survival has been reported with CRS alone.⁵,⁷⁻⁸

In contrast, IPC provides clinical benefit as adjunct to CRS in peritoneal carcinomatosis from gastric and ovarian cancer.⁸⁻⁹ Furthermore, IPC in PMP differs between...
treatment centres in terms of drug selection, dosing, and timing of the IPC.\textsuperscript{8,10} Thus, IPC as part of treatment of PMP is in need of further investigation to define its role and provide a basis for how to optimize this resource demanding treatment step.

We used a short-term ex vivo assay to evaluate the tumor cell sensitivity to cytotoxic drugs in samples from PMP patients undergoing CRS and IPC. The goals were to provide information on the pattern of drug activity in PMP and to correlate the ex vivo drug sensitivity pattern to the clinical outcome.

**METHODS**

**Patients and Tumor Samples**

A total of 133 patients scheduled for CRS and HIPEC for PMP at the Department of Surgery, Uppsala University Hospital between May 2006 and December 2011, and from which a tumor sample for ex vivo assessment of drug activity was obtained, formed the basis for the study. Tumor sampling was performed intraoperatively prior to HIPEC, which consisted of 30–35 mg/m\textsuperscript{2} of mitomycin C, 100 mg/m\textsuperscript{2} of cisplatin combined with 15 mg/m\textsuperscript{2} of doxorubicin or 360 mg/m\textsuperscript{2} of both irinotecan and oxaliplatin.\textsuperscript{4} Tumor sampling and data collection was based on patient informed consent and approved by the Regional Ethical Review Board in Uppsala (Dnr 2007/237). None of the patients had adjuvant systemic chemotherapy following CRS and HIPEC.

Tumor histopathology was classified as disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), or PMCA with intermediate features.\textsuperscript{11} Tumor load was assessed as the Peritoneal Cancer Index (PCI) at time of surgery.\textsuperscript{12} Residual disease after a CRS and HIPEC, which consisted of 30–35 mg/m\textsuperscript{2} of mitomycin C, 100 mg/m\textsuperscript{2} of cisplatin combined with 15 mg/m\textsuperscript{2} of doxorubicin or 360 mg/m\textsuperscript{2} of both irinotecan and oxaliplatin.\textsuperscript{4} Tumor sampling and data collection was based on patient informed consent and approved by the Regional Ethical Review Board in Uppsala (Dnr 2007/237). None of the patients had adjuvant systemic chemotherapy following CRS and HIPEC.

Tumor histopathology was classified as disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA), or PMCA with intermediate features.\textsuperscript{11} Tumor load was assessed as the Peritoneal Cancer Index (PCI) at time of surgery.\textsuperscript{12} Residual disease after a maximal surgical effort was quantified according to the completeness of cytoreduction score (CC). CC scores 0 (no macroscopic tumor left) and 1 (residual tumor <0.25 cm) were considered as complete cytoreduction.\textsuperscript{13}

**Ex Vivo Assessment of Drug Sensitivity**

The tumor specimen was kept in buffer at 6 °C until preparation. Tumor cells were prepared by collagenase digestion as described.\textsuperscript{14} The cells obtained were mostly single cells or small cell clusters with ≥90 % viability and with <30 % contaminating nonmalignant cells, as judged by morphological examinations of May-Grünwald-Giemsa-stained cytocentrifugate preparations.

The drugs used for HIPEC (see above) were tested ex vivo. In addition, 5FU, an established drug in gastrointestinal cancer treatment, was included. All drugs were from commercially available clinical preparations. The drugs were tested at three tenfold dilutions from the maximal concentration (µM) of 100 for cisplatin, 100 for oxaliplatin, 10 for doxorubicin, 1000 for 5FU, 100 for mitomycin C, and 1000 for irinotecan. The drug concentrations used ex vivo are chosen empirically to produce concentration—response curves allowing for extraction of 50 % inhibitory concentrations (IC\textsubscript{50}), i.e., the drug concentration producing a cell survival of 50 % compared with an unexposed control. The maximal concentrations used ex vivo are close to \( C_{\text{max}} \) achievable during IPC for most drugs.\textsuperscript{15} 384-well microplates (Nunc) were prepared with 5-µl drug solution at 10 × the final drug concentration using the pipetting robot BioMek 2000 (Beckman Coulter). The plates were then stored at −70 °C until further use.

The semiautomated fluorometric microculture cytotoxicity assay (FMCA) was used to assess drug sensitivity.\textsuperscript{16} Briefly, tumor cells from patient samples (5000 cells/well in 45 µl culture medium RPMI 1640 (supplemented with 10 % foetal calf serum, glutamine and antibiotics) were seeded in the drug-prepared 384-well plates using the pipetting robot Precision 2000 (Bio-Tek Instruments Inc., Winooski, VT). Three columns without drugs served as controls and one column with medium only served as blank.

The culture plates were incubated at 37 °C in humidified atmosphere containing 95 % air and 5 % CO\textsubscript{2}. After 72 h incubation, the culture medium was washed away and 50 µl/well of a physiological buffer containing 10 µg/ml of the vital dye fluorescein diacetate (FDA) were added to control, experimental, and blank wells. After incubation for 30–45 min at 37 °C, the fluorescence from each well was read in a FluoroScan 2 ( Labsystems OY, Helsinki, Finland).

Quality criteria for a successful assay were: ≥70 % tumor cells in the cell preparation before incubation and/or on the assay day, a fluorescence signal in control cultures of ≥5 x mean blank values, and a coefficient of variation of cell survival in control cultures of ≤30 %. The results obtained by the viability indicator FDA are calculated as survival index (SI), defined as the fluorescence of the test expressed as a percentage of control cultures, with blank values subtracted.

**Patient Data and Follow-Up**

Clinical data relevant for the study were retrieved from the patient files. Patients with complete cytoreduction were followed for progression-free survival (PFS) by assessment of serum tumor markers (CEA, CA19-9, CA 125, and CA 72.3) every 3 months and with CT scan of abdomen and thorax every 6 months for 3 years and then every 12 months, for another 2 years. An increase in a tumor marker ≥25 % triggered a CT scan for verification of new
lesions consistent with PMP relapse. Overall survival (OS) was assessed from registry data up to February 2014. Data on treatment following relapse was incomplete and indicated individualized approaches used. This is expected to affect the OS observed probably making this endpoint poorly associated to the IPC (see “Results” section).

Data Evaluation and Statistics

IC\textsubscript{50} was calculated using non-linear regression to a standard sigmoidal dose–response model in GraphPad Prism version 5 for Mac (GraphPad Software, San Diego, CA). Alternatively, sample sensitivity was scored according to the SI at the highest cytotoxic drug concentration used ex vivo. In this case, low drug resistance (LDR) was defined as a SI below the median, intermediate drug resistance (IDR) as a SI between the median and median plus two standard deviations (SDs), and extreme drug resistance (EDR) as a SI above median plus two SDs based on all samples investigated ex vivo.\textsuperscript{16,17}

Statistical inferences between several means were performed by one-way ANOVA with Tukey HSD post-hoc tests. The prognostic importance of clinicopathological variables and ex vivo drug sensitivity for OS and PFS was assessed in a Cox regression model. In the model on OS only univariate results with \( p < 0.2 \) were included in the final multivariable analysis. Analyses on PFS were adjusted for WHO performance status, histopathological subtype, and tumor load. The level of significance for all statistical tests was set to \( p < 0.05 \). Data are presented as mean ± SD unless otherwise stated.

RESULTS

A successful ex vivo assay fulfilling the quality criteria was obtained from 92 tumor samples (69 %) and data from these patients were included for analysis in the study. Mucin-rich tumor samples, often of the DPAM subtype, dominated among samples not possible to run in the assay due to difficulties to recover a sufficient number of epithelial cells when a lot of mucin was present during cell preparation. The majority of patients had a histopathology of DPAM (\( n = 57 \)), whereas 24 had PMCA and 11 patients had a PMCA intermediate histology (Table 1). A majority of patients, 64 %, had previously been treated systemically and/or locally with chemotherapy for PMP. In 61 patients (66 %) CC 0–1, i.e., complete cytoreduction was achieved at CRS. Eighty patients, including 59 of the 61 patients with complete cytoreduction, received HIPEC, most commonly single drug mitomycin C (\( n = 56 \)), combinations of cisplatin and doxorubicin (\( n = 17 \)), or irinotecan and oxaliplatin (\( n = 7 \)).

| TABLE 1 | Clinical characteristics of the pseudomyxoma peritonei samples successfully analyzed ex vivo (\( n = 92 \)) |
|-------------|----------------------------------------------------------|
| Age, year, mean (range) | 56 (24–78) |
| BMI, kg/m\textsuperscript{2}, mean (range) | 25 (19–38) |
| Male/female | 47/45 |
| Histopathology | DPAM 57 (62 %), PMCA intermediate 11 (12 %), PMCA 24 (26 %) |
| Prior chemotherapy | No 59 (64 %), Yes 33 (36 %) |
| PCI score\textsuperscript{a} | 1–10 9 (10 %), 11–20 13 (14 %), 21–39 69 (76 %) |
| WHO performance status | 0 79 (86 %), 1–2 13 (14 %) |
| Complete cytoreductive surgery\textsuperscript{b} | 61 (66 %) |
| Hyperthermic intraperitoneal chemotherapy | 80 (87 %) |

\textsuperscript{DPAM} disseminated peritoneal adenomucinosis, \textsuperscript{PMCA} peritoneal mucinous carcinomatosis, \textsuperscript{PCI} peritoneal carcinoma index, \textsuperscript{WHO} World Health Organization

\textsuperscript{a} Information on PCI score unavailable in one patient

\textsuperscript{b} CC score 0–1

Drug sensitivity varied considerably between patient samples as indicated by the high SDs observed for the IC\textsubscript{50} values for all drugs (Table 2). Samples obtained from patients previously exposed to cytotoxic drugs were statistically significantly more resistant to all drugs tested except irinotecan. There were statistically significant differences in drug sensitivity to oxaliplatin, 5-FU, and cisplatin between the histopathological subtypes of PMP (Table 2); PMCA showed higher IC\textsubscript{50} values for oxaliplatin, 5-FU, and cisplatin compared with samples of hybrid histology. Similarly, PMCA samples had higher IC\textsubscript{50} for oxaliplatin than DPAM. There were no statistically significant differences in drug sensitivity between samples divided into low and high grade according to Bradley (Supplementary Table 1).\textsuperscript{18}

Analysis of OS according to clinical variables, histopathology, and drug sensitivity were performed by uni- and multivariable Cox regression for all patients with successful ex vivo assay (\( n = 92 \); Supplementary Table 2). Drug sensitivity was not statistically significantly associated with OS (univariate hazard ratio range, 0.59–1.20), whereas, as expected, impaired WHO performance status and completeness of cytoreduction (no vs. yes) were associated with shorter OS (hazard ratio, 7.93 and 11.73, respectively; \( p < 0.001 \)).
Because of the strong prognostic value of complete cytoreductive surgery, subsequent analyses on prognostic impact of ex vivo drug sensitivity were performed in patients with complete cytoreduction \((n = 61)\) with PFS as the clinical endpoint. Because only five patients in this group died during follow-up, analysis on OS was not considered. Following adjustment for performance status, PCI score, and histopathologic subtype, a strong trend towards longer PFS was observed for individuals with tumors sensitive to mitomycin C and cisplatin, indicating that our material and the findings are representative for PMP.4,5

The fact that the extent of CRS was strongly associated with OS, whereas ex vivo drug sensitivity was not, points to the importance of qualified surgery to achieve long-term survival in PMP. However, ex vivo drug sensitivity provided prognostic information for PFS and points to a possible impact of IPC on PFS when added to CRS. These observations are largely in line with previous findings pointing to a benefit from HIPEC for PFS but not OS as well as the possibility to achieve long-term OS with surgery alone.4,5,21–23 Still, a prolongation of PFS from IPC is considered clinically relevant, because it is reasonably associated with less disease-related symptoms and, thus, improved quality of life.

The observations indicating that IPC has limited effect and require good CRS make sense from a tumor biology point of view, because the penetration of cytotoxic drugs into tumor tissue is very limited. Thus, no substantial effect of IPC on macroscopic tumor lesions is to be expected.8 Still, some effect from IPC in the presence of remaining macroscopic disease following CRS cannot be excluded. In our series, patients without complete CRS who had HIPEC \((n = 21)\) had a OS of 63 versus 7 months for those who had not \((n = 10)\), a difference that was statistically significant also after adjustment for performance status, histopathology, and PCI \((p = 0.007; \text{not shown})\). However, patient selection based on other prognostic factors reasonably explains most of this difference.

Our finding that ex vivo drug sensitivity provided prognostic information for PFS points to a possible impact of IPC on PFS when added to CRS. Still, it cannot be excluded that ex vivo drug sensitivity is only a prognostic marker reflecting tumor behavior unrelated to a therapeutic effect from IPC. The only way to differentiate between a
purely prognostic vs predictive impact from ex vivo drug sensitivity assessment would be a clinical trial in which IPC is guided by ex vivo drug sensitivity data. This would be a way to try to improve the effect of IPC by individualized selection of active drug(s) but also to decrease treatment related toxicity by avoiding IPC if no drugs seem active. The large interindividual sample differences in drug sensitivity that we observed clearly point to the potential for IPC individualization. Such trial would be technically feasible, because tumor tissue for ex vivo analysis could be obtained by laparoscopy before the CRS and ex vivo drug sensitivity data can be obtained within a few days. Such study is presently under discussion at our center.

### Table 3

Univariate and multivariate Cox regression model for progression-free survival according to dichotomized drug sensitivity values (below vs. above the median IC$_{50}$) and clinicopathological variables in pseudomyxoma peritonei patients with complete cytoreductive surgery ($n = 61$)

| Drug            | Univariate hazard ratio | $p$  | Multivariate hazard ratio$^a$ | $p$  |
|-----------------|-------------------------|------|-------------------------------|------|
| Oxaliplatin     | 1.33                    | 0.6  | 0.96                          | 1.0  |
| 5-FU            | 1.24                    | 0.7  | 0.98                          | 1.0  |
| Mitomycin C     | 0.66                    | 0.4  | 0.36                          | 0.063|
| Doxorubicin     | 1.49                    | 0.5  | 1.21                          | 0.8  |
| Irinotecan      | 0.95                    | 1.0  | 0.72                          | 0.6  |
| Cisplatin       | 0.54                    | 0.3  | 0.36                          | 0.062|

$^a$ Adjusted for histopathological subtype, PCI score, and WHO performance status

### Table 4

Univariate and multivariable Cox regression model for progression-free survival according to drug sensitivity at the highest cytotoxic drug concentration used ex vivo in pseudomyxoma patients with complete cytoreductive surgery ($n = 61$)

| Drug            | n   | Univariate hazard ratio | $p$  | Multivariate hazard ratio$^a$ | $p$  |
|-----------------|-----|-------------------------|------|-------------------------------|------|
| Mitomycin C     |     |                         |      |                               |      |
| LDR             | 35  | 1                       |      |                               |      |
| IDR             | 22  | 2.32                    | 0.2  | 3.38                          | 0.05 |
| EDR             | 4   | 5.19                    | 0.05 | 6.00                          | 0.05 |
| Cisplatin       |     |                         |      |                               |      |
| LDR             | 35  | 1                       |      |                               |      |
| IDR             | 20  | 1.86                    | 0.3  | 3.00                          | 0.064|
| EDR             | 4   | 5.16                    | 0.05 | 14.35                         | 0.001|
| Imitotecan      |     |                         |      |                               |      |
| LDR             | 30  | 1                       |      |                               |      |
| IDR             | 26  | 1.38                    | 0.6  | 1.53                          | 0.5  |
| EDR             | 5   | 1.93                    | 0.5  | 1.68                          | 0.6  |
| 5FU             |     |                         |      |                               |      |
| LDR             | 30  | 1                       |      |                               |      |
| IDR             | 26  | 0.52                    | 0.3  | 0.55                          | 0.4  |
| EDR             | 4   | 3.83                    | 0.05 | 4.91                          | 0.05 |
| Oxaliplatin     |     |                         |      |                               |      |
| LDR             | 33  | 1                       |      |                               |      |
| IDR             | 24  | 0.68                    | 0.7  | 2.26                          | 0.2  |
| EDR             | 3   | 1.28                    | 0.9  | 3.52                          | 0.3  |
| Doxorubicin     |     |                         |      |                               |      |
| LDR             | 32  | 1                       |      |                               |      |
| IDR             | 20  | 1.05                    | 1.0  | 1.03                          | 1.0  |
| EDR             | 7   | 1.8                     | 0.4  | 1.76                          | 0.5  |

$^a$ Adjusted for histopathological subtype, PCI score, and WHO performance status
Given that standard protocol IPC is currently part of the standard treatment for PMP, which conclusions can be drawn from the current study? The PMP samples in this study were essentially equally drug sensitive as peritoneal metastasis samples of colorectal cancer analyzed ex vivo with the same technique. Because several of the drugs analyzed are active in the treatment of colorectal cancer, similar drug activity also could be expected in PMP, provided similar drug exposure as in IPC.

The IC$_{50}$ values for cisplatin and oxaliplatin were almost identical in the PMP subgroups. Given that a considerably higher dose of oxaliplatin compared with cisplatin can be given in IPC, the platinum of choice for IPC in PMP to achieve maximum effect is suggested to be oxaliplatin.

There were no major differences in drug sensitivity between the histopathological PMP subtypes, indicating that IPC protocols for PMP do not need to consider histopathological subtype. Furthermore, the frequently observed poor prognosis of PMCA compared with DPAM seems related to tumor biological factors other than tumor cell drug sensitivity.

The large interindividual differences in sensitivity to drugs used in IPC among the PMP samples were substantial. A reasonable interpretation is that IPC may be a more or less futile treatment step for patients with drug resistant tumor cells and that these patients would be better off with CRS alone.

Finally, tumor cells from patients previously exposed to cytotoxic drugs were generally more drug resistant than those previously unexposed. This is in line with the clinical observation that prior chemotherapy was associated with impaired prognosis in PMP. Because systemic chemotherapy seems not very active in PMP, it might be argued that PMP patients should go directly to CRS and HIPEC rather than be started on systemic chemotherapy with the risk for disease progression and development of drug resistance.

CONCLUSIONS

Ex vivo assessment of tumor cell sensitivity to cytotoxic drugs provides prognostic information in PMP and may be useful for sparing the most resistant patients from IPC expected to be futile. However, whether selection of drugs for IPC in PMP based on ex vivo assessment also is predictive for a treatment effect, and thus could be used for treatment individualization, needs to be investigated in a prospective, clinical trial.

ACKNOWLEDGMENT The skillful technical assistance of Kristin Blom, Annika Jonasson, and Anna-Karin Lannerågard for the ex vivo assessment of drug sensitivity is gratefully acknowledged. This study was supported by grants from the Swedish Cancer Society and Lions Cancer Research Fund.

DISCLOSURE None of the authors have any conflicts of interest to declare.

OPEN ACCESS This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
REFERENCES

1. Szych C, Staebler A, Connolly D, Wu R, Cho K, Ronnet B. Molecular genetic evidence supporting the clonality and appendiceal origin of pseudomyxoma peritonei in women. Am J Pathol. 1999;154:1849–55.

2. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7:69–76.

3. McBride K, McFadden D, Osler T. Improved survival of patients with pseudomyxoma peritonei receiving intraperitoneal chemotherapy with cytoreductive surgery: a systematic review and meta-analysis. J Surg Oncol. 2013;108:246–52.

4. Andréasson H, Graf W, Nygren P, Glimelius B, Mahteme H. Outcome differences between debulking surgery and cytoreductive surgery in patients with pseudomyxoma peritonei. Eur J Surg Oncol. 2012;38:962–8.

5. Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449–56.

6. Sugarbaker PH, Chang D, Yoo D. Neoadjuvant Folfox chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102:836–44.

7. Nakakura EK. Pseudomyxoma peritonei: more questions than answers. J Clin Oncol. 2012;30:2429–30.

8. Ceelen WP, Flessner MF. Intrapерitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nature Rev Clin Oncol. 2010;7:108–15.

9. Yang X-J, Huang C-Q, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18:575–81.

10. Winder T, Lenz H-J. Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. Oncologist. 2010;15:836–44.

11. Ronnet BM, Zahn CM, Kurman RJ, Kass ME, Sugarbaker PH, Shmookler BM. Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathological analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei.” Am J Surg Pathol. 1995;19:1390–408.

12. Sugarbaker PH. Peritomectomy procedures. Ann Surg. 1995;221:29–42.

13. Moran B, Baratti D, Yan TD, Kusamura S, Deraco M. Consensus statement on the loco-regional treatment of appendiceal mucinous neoplasms with peritoneal dissemination (pseudomyxoma peritonei). J Surg Oncol. 2008;98:277–82.

14. Csoka K, Tholander B, Gerdin E, de la Torre M, Larsson R, Nygren P. In vitro determination of cytotoxic drug-response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1997;72:1008–12.

15. Cashin P, Mahteme H, Graf W, Karlsson H, Larsson R, Nygren P. Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer. BMC Cancer. 2013;13:374.

16. Lindhagen E, Nygren P, Larsson R. The fluorometric microculture cytotoxicity assay. Nat Protocols. 2008;3:1364–9.

17. Larsson R, Fridborg H, Kristensen J, Sundström C, Nygren P. In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer. 1993;67:969–74.

18. Bradley RF, Stewart JH, Russel GB, Levine EA, Geisinger KR. Pseudomyxoma peritonei of appendiceal origin: a clinicopathological analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551–9.

19. Nygren P, Hagberg H, Glimelius B, Sundström C, Kristensen J, Christiansen I, Larsson R. In vitro drug sensitivity testing of tumor cells from patients with non-Hodgkin’s lymphoma using the fluorometric microculture cytotoxicity assay (FMCA). Ann Oncol. 1994;5:127–31.

20. Nygren P, Fridborg H, Csoka K, et al. Detection of tumor specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 1994;56:715–20.

21. Miner T, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei. An analysis of surgical therapy. Ann Surg. 2005;241:300–8.

22. Järvinen P, Järvinen HJ, Lepistö A. Survival of patients with pseudomyxoma peritonei treated by serial debulking. Colorectal Dis. 2010;12:868–72.

23. Gough D, Donohue J, Schutt A, et al. Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. 1994;219:112–9.